Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis

Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation 1. While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growin...

Full description

Bibliographic Details
Main Authors: Céline Eldani, Marie Kostine, Maxime Faure, Estibaliz Lazaro, Claire Rigothier, Jean Baptiste Hiriart, Bérénice Teulières, Florian Poullenot, Magalie Haissaguerre, Maeva Zysman, Rémi Veillon, Charlotte Vergnenegre, Nahema Issa, Charlotte Domblides, Sorilla Mary-Prey, Marie Beylot-Barry, Anne Pham-Ledard, Caroline Dutriaux, Guilhem Sole, Fanny Duval, Emilie Gerard
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitors (ICIs)
immune related adverse events (irAEs)
rechallenge
neurological immune-related adverse events
myocarditis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1403658/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1403658/full

Similar Items